https://orcid.org/0000-0002-0140-0538
Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T. Gerds, Angela Fleischman & Srdan Verstovsek. (2023) Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia & Lymphoma 64:6, pages 1063-1081.
Read now
Read now
James T. England & Vikas Gupta. (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy 23:15, pages 1677-1686.
Read now
Read now
Articles from other publishers (10)
Naveen Pemmaraju, Jacqueline S. Garcia, Andrew Perkins, Jason G. Harb, Andrew J. Souers, Michael E. Werner, Christopher M. Brown & Francesco Passamonti. (2023)
New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X
L
/BCL‐2 inhibition with navitoclax
. Cancer 129:22, pages 3535-3545.
Crossref
Crossref
T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge & D. J. Touw. (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clinical Pharmacokinetics 62:4, pages 559-571.
Crossref
Crossref
Naveen Pemmaraju, Srdan Verstovsek, Ruben Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner & Adam J. Mead. (2022) Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128:13, pages 2420-2432.
Crossref
Crossref
Francesco Passamonti, Florian H Heidel, Rohan C Parikh, Mayank Ajmera, Derek Tang, Jose Alberto Nadal, Keith L Davis & Pranav Abraham. (2022) Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncology 18:18, pages 2217-2231.
Crossref
Crossref
Donal P. McLornan, Christopher J. Saunders & Claire N. Harrison. (2022) Considerations to comprehensive care for the older individual with myelofibrosis. Best Practice & Research Clinical Haematology 35:2, pages 101371.
Crossref
Crossref
James England & Vikas Gupta. (2021) Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?. Hematology 2021:1, pages 453-462.
Crossref
Crossref
Sasirekha Pandravada & Steven Sandler. (2021) The Role of Navitoclax in Myelofibrosis. Cureus.
Crossref
Crossref
David M. Ross, Jeffrey J. Babon, Denis Tvorogov & Daniel Thomas. (2021) Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Haematologica 106:5, pages 1244-1253.
Crossref
Crossref
Yammy Yung, Emily Lee, Hiu-Tung Chu, Pui-Kwan Yip & Harinder Gill. (2021) Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. International Journal of Molecular Sciences 22:2, pages 659.
Crossref
Crossref
Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A. Robertson, Xue Lei, Helen J. S. Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Andrew Davis, Jonathan Lopez, Jun-ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Karen Blyth, Mhairi Copland, Timothy J. T. Chevassut, Karen Keeshan & Peter D. Adams. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications 12:1.
Crossref
Crossref